Dactinomycin (Ac-De)

A compound composed of a two CYCLIC PEPTIDES attached to a phenoxazine that is derived from STREPTOMYCES parvullus. It binds to DNA and inhibits RNA synthesis (transcription), with chain elongation more sensitive than initiation, termination, or release. As a result of impaired mRNA production, protein synthesis also declines after dactinomycin therapy. (From AMA Drug Evaluations Annual, 1993, p2015)

Also Known As:

Networked: 1691 relevant articles (64 outcomes, 169 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Green, Daniel M: 8 articles (01/2014 - 06/2003)
2.	Thompson, John F: 7 articles (03/2014 - 01/2006)
3.	Ritchey, Michael L: 7 articles (01/2014 - 06/2003)
4.	Breslow, Norman E: 7 articles (01/2014 - 09/2004)
5.	Shamberger, Robert C: 7 articles (01/2014 - 06/2003)
6.	Beckwith, J Bruce: 6 articles (01/2014 - 06/2003)
7.	Anderson, James R: 5 articles (11/2014 - 11/2009)
8.	Xiang, Yang: 5 articles (08/2014 - 06/2004)
9.	Kam, Peter C A: 5 articles (03/2014 - 05/2009)
10.	Thomas, Patrick R M: 5 articles (01/2014 - 09/2004)

Related Diseases

1.	Neoplasms (Cancer) 10/05/2003 - "As actinomycin D treatment in children with cancer is associated with veno-occlusive disease (VOD), and as the dose intensity of actinomycin D treatment has been defined as a significant risk factor for the development of this potentially life-threatening hepatic toxicity, pharmacokinetic studies of actinomycin D may be beneficial in optimizing treatment with this drug. " 01/01/1974 - "In addition, some evidence is cited suggesting that actinomycin D may be more effective against certain tumors when employed in lower, chronic dosages rather than its present use in "loading" dosages.The" 12/01/2013 - "In the present study, we reported that methylated actinomycin D (mAct D), a novel actinomycin D analog isolated from Streptomyces sp. KLBMP 2541 in our previous study, could not only exert stronger inhibitory effects on several human cancer cells than Act D in dose- and time-dependent manner at ng concentrations, especially on HepG2 cells, but also lower cytotoxicity in normal cells (HL-7702). " 08/15/2005 - "Pharmacokinetics of dactinomycin in a pediatric patient population: a United Kingdom Children's Cancer Study Group Study." 01/01/1999 - "In this study, we showed that the p53 response to a chemotherapeutic drug, actinomycin D, was reversible in both normal and tumor cells, even when a substantial proportion of tumor cells were undergoing apoptosis. "
2.	Wilms Tumor (Wilm's Tumor) 03/21/1966 - "Role of dactinomycin in the improved survival of children with Wilms' tumor." 09/19/1964 - "NEPHROBLASTOMA (WILMS' TUMOUR): IMPROVED PROGNOSIS WITH ACTINOMYCIN D." 07/25/1964 - "NEPHROBLASTOMA (WILMS' TUMOUR): IMPROVED PROGNOSIS WITH ACTINOMYCIN D." 09/01/2008 - "This phase 2 pediatric trial evaluated the efficacy and further defined the toxicity profile of recombinant TNF (rTNF) and dactinomycin in patients with recurrent or refractory Wilms tumor. " 12/01/2002 - "Clinical studies of actinomycin D with special reference to Wilms' tumor in children. "
3.	Melanoma (Melanoma, Malignant) 05/01/1967 - "Induced remission of malignant melanoma with actinomycin D. " 05/01/2000 - "Autologous MABs from melanoma cells following actinomycin D treatment (0.5 microgram/ml) for 24 hours, were added to 72 hour DC culture. " 09/15/1998 - "Furthermore, addition of actinomycin D to TRAIL-resistant melanomas resulted in decreased intracellular concentrations of FLIP, which correlated with their acquisition of TRAIL sensitivity. " 05/01/1987 - "The presence of actinomycin D during gamma-irradiation of human melanoma cells leads to an increased radiosensitivity under aerobic and hypoxic conditions. " 05/01/1987 - "[The effect of actinomycin D on the survival and recoverability of irradiated human melanoma cells]."
4.	Lymphoma (Lymphomas) 08/01/2008 - "To evaluate response rate and disease-free interval in dogs with relapsed or resistant lymphoma treated with actinomycin D, determine hematologic toxicoses, and identify prognostic factors associated with response to treatment. " 09/01/1994 - "Actinomycin D for reinduction of remission in dogs with resistant lymphoma." 08/01/2008 - "Actinomycin D as rescue therapy in dogs with relapsed or resistant lymphoma: 49 cases (1999--2006)." 10/01/1987 - "Actinomycin D was clastogenic and mutagenic in L5178Y/TK +/- -3.7.2C mouse lymphoma cells. " 01/01/2006 - "The results of this study warrant further investigation into the value of extended maintenance therapy and inclusion of actinomycin-D in combination chemotherapy protocols for canine lymphoma."
5.	Ewing's Sarcoma (Sarcoma, Ewing) 04/01/1970 - "Treatment of metastatic Ewing's sarcoma with actinomycin D (NSC-3053)." 01/01/2004 - "In this study, we showed that etoposide and actinomycin D kill Ewing tumor cells (RD-ES cell line) mainly via a caspase-dependent mechanism. " 10/05/2003 - "Actinomycin D is an anti-cancer drug commonly used in the treatment of paediatric malignancies such as Wilms' tumour, Ewing's sarcoma and rhabdomyosarcoma. " 10/16/1991 - "Increasing dactinomycin dose intensity was associated with a poorer outcome in treatment of osteogenic sarcoma and Ewing's sarcoma, most likely resulting from regimens with a higher dactinomycin dose intensity having a lower doxorubicin dose intensity. " 01/01/1998 - "A higher rate of good responses was achieved with the use of ifosfamide and dactinomycin in addition to a conventional three-drug VAC regimen, suggesting that these drugs should be included from the beginning in neoadjuvant regimens for the treatment of Ewing's sarcoma. "

Related Drugs and Biologics

1.	Vincristine (Oncovin)
2.	Cyclophosphamide (Cytoxan)
3.	Doxorubicin (Adriamycin)
4.	Etoposide (VP 16)
5.	Methotrexate (Mexate)
6.	Cisplatin (Platino)
7.	Ifosfamide
8.	Vinblastine (Vinblastine Sulfate)
9.	Bleomycin (Blenoxane)
10.	Fluorouracil (Carac)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Combination Drug Therapy (Combination Chemotherapy)
3.	Radiotherapy
4.	Aftercare (After-Treatment)
5.	Adjuvant Chemotherapy